Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market

Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.
Source: Healthcare News - Category: Pharmaceuticals Authors: Tags: OTCMKTS:BAYRY NYSE:LLY NASDAQ:HCM Source Type: news

Related Links:

Publication date: Available online 22 April 2019Source: Colloids and Surfaces A: Physicochemical and Engineering AspectsAuthor(s): Shengtao Wang, Jingtao Li, Zhou Ye, Jieling Li, Anhe Wang, Jing Hu, Shuo Bai, Jian YinAbstractHerein, an amphipathic polymeric photosensitizer, designated as PEGylated distyryl boron dipyrromethenes with real-time tracing property, is synthesized as a kind of multifunctional carrier to load drugs for combined photodynamic-chemo therapy. The hydrophilic PEG side chains on the carriers prolong its blood circulation time and the self-assembly capacity of PEGylated distyryl boron dipyrromethenes ef...
Source: Colloids and Surfaces A: Physicochemical and Engineering Aspects - Category: Chemistry Source Type: research
In this study, hyaluronic acid (HA)- and carboxymethyl cellulose sodium (CMCNa)-based novel cross-linked hydrogels (HC hydrogels) were synthesized and fully characterized. We demonstrated that varied compositions of HA and CMCNa altered the microstructure, rheology, and degradation behavior of hydrogels. Pre-constructed hydrogels were further loaded with oxaliplatin to prevent intra-abdominal adhesion following chemotherapy. Sustained release of oxaliplatin was observed from hydrogels compared that from solutions, which release drugs through diffusion, following the Higuchi and Korsmeyer-Peppas models. Moreover, low adhesi...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
This is the last week to register at the discounted early registration rates for the 18th MIXiii-BIOMED Conference and Exhibition, taking place May 14-16 at The David InterContinental Hotel, Tel Aviv, Israel. As Israel’s lea...
Source: Medgadget - Category: Medical Devices Authors: Tags: Sponsored Content Source Type: blogs
ConclusionsFindings confirm high 1-year mortality for advanced HCC, suggesting a high cost burden. While no 2L therapy was available during this analysis, recently approved 2L agents have the potential to improve survival after sorafenib failure or intolerance.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
The U.S. Food and Drug Administration has approved Merck&Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Publication date: Available online 19 April 2019Source: Seminars in Cancer BiologyAuthor(s): Lingzhi Li, Zhuoyu Bi, Priya Wadgaonkar, Yongju Lu, Qian Zhang, Yao Fu, Chitra Thakur, Li Wang, Fei ChenAbstractAt present, the belief that genetic mutations control every aspect of tumorigenesis is still very popular. Even for the highly debated “bad luck” theory of cancers, it ascertained that random mutation of genes during the self-renewal of somatic stem cells is responsible for cancer initiation. Logically, most of the new therapeutic strategies so far, from molecular targeting to precision medicine or personalize...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 April 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Jingwen Shi, Shuiping Liu, Yuan Yu, Changyu He, Lianjiang Tan, Yu-Mei ShenAbstractDevelopment of polymer-drug conjugate capable of controlled drug release is urgently needed for gastric cancer therapy. Herein, arginine-glycine-aspartic acid (RGD)-decorated polyethylene glycol (PEG)-paclitaxel (PTX) conjugates containing disulfide linkage were synthesized. The amphiphilic PEG-PTX conjugates were found to assemble into micelles (RGD@Micelles), which would be decomposed under the reduction of glutathione (GSH) and finally ...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: Available online 18 April 2019Source: Pharmacological ResearchAuthor(s): Filipe J. Teixeira, Heitor O. Santos, Scott L. Howell, Gustavo D. PimentelAbstractCancer remains a public health challenge in the identification and development of ideal pharmacological therapies and dietary strategies. The use of whey protein as a dietary strategy is widespread in the field of oncology. The two types of whey protein, sweet or acid, result from several processing techniques and possess distinct protein subfraction compositions. Mechanistically, whey protein subfractions have specific anti-cancer effects. Alpha-lactal...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 April 2019Source: Nano TodayAuthor(s): Arif Gulzar, Jiating Xu, Chen Wang, Fei He, Dan Yang, Shili Gai, Piaoping Yang, Jun Lin, Dayong Jin, Bengang XingAbstractThe tumour mass is made up of not only of a heterogeneous population of cancer cells nonetheless also a mixture of resident as well as the infiltrating host cells, secreted factors besides extracellular matrix proteins, together recognized as the tumour microenvironment (TME). Tumour development is overwhelmingly affected through the dealings of cancer cells with their environment which eventually conclude whether the primary tu...
Source: Nano Today - Category: Nanotechnology Source Type: research
The phosphoinositide 3-kinase (PI3K) signaling pathway is frequently activated in human cancer due to activating mutations in PI3Ks or the loss of phosphatase and tensin homologue (PTEN) function. In addition to its canonical role as a regulator of cellular proliferation and survival, the PI3K pathway has been implicated in promoting resistance to immune-based anti-cancer therapies. To further define how PI3K signaling may promote tumor cell immune escape, we examined the impact of PI3K inhibition and activation on the induction of MHC class I (MHCI) and II (MHCII) molecules by interferon-gamma (IFN-g).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | China Health | Partnerships